|
Name: PB-22 (Quinolin-8-yl 1-pentyl-1H-indole-3-carboxylate)
Type: Synthetic cannabinoid
AKA: QUPIC; PB-22
|
|
II. Natural Derivative
Synthetic substance, no natural derivative
 |
|
|
IV. History
PB-22, a synthetic cannabinoid, was developed in the early 2010s. It is part of a class of substances used in research for their psychoactive effects on cannabinoid receptors. Its historical role includes contributions to the understanding of synthetic cannabinoids and their legal and cultural implications.
|
|
V. Legal Information
PB-22 is a synthetic cannabinoid often found in designer drugs. It is regulated as an analog of THC in many jurisdictions. In the U.S., it is prosecuted under the Federal Analog Act if it mimics controlled substances. Internationally, many countries have included PB-22 in their controlled substance lists due to its psychoactive effects. The trend is toward stricter regulation to address synthetic cannabinoid abuse. [Source: UNODC].
US Federal Schedule - I
Schedule I drugs, substances, or chemicals are defined as drugs with no currently accepted medical use and a high potential for abuse. Some examples of Schedule I drugs are: heroin, lysergic acid diethylamide (LSD), marijuana (cannabis), 3,4-methylenedioxymethamphetamine (ecstasy), methaqualone, and peyote.
Key US Federal Policies:
Controlled Substances Act. Public Law: Public Law 91-513 (text can be found on GovInfo) (https://www.dea.gov/drug-information/csa). Date enacted: October 27, 1970.
|
|
VI. Physical Effects
PB-22 is a synthetic cannabinoid with psychoactive effects. It acts as an upper, causing euphoria and altered perception. Short-term use can lead to intense psychological effects, while long-term impacts are poorly understood. Overdose risks include severe psychological distress and potential toxicity. Safe use is uncertain due to limited research. Recent studies focus on its psychoactive properties and health risks.  |
|
VII. Psychological Effects
PB-22, a synthetic cannabinoid, causes euphoria, altered perception, and anxiety. Immediate impacts include paranoia and cognitive impairment. Long-term use can lead to dependence, severe psychiatric disorders, and cognitive deficits. Recent research indicates higher risks of severe anxiety and psychotic episodes compared to natural cannabinoids.
 |
|
VIII. Culture
PB-22 is a synthetic cannabinoid, classifying it as a downer. Short-term use induces relaxation and altered perceptions, while long-term use can lead to dependence and cognitive impairment. Overdose risks include severe sedation, cognitive effects, and potential psychosis. Safe dosages are not well-established, with minimal use recommended. Recent research highlights its high potency and associated risks of cognitive effects. Physical effects include drowsiness, altered perceptions, and potential for impaired motor skills.
 |